Related Experiment Video
Updated: May 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Patient with testosterone deficit syndrome after radical prostatectomy]
Estefanía Linares Espinós1, Juan I Martínez-Salamanca, Abraham Morgentaler
1Servicio y Catedra de Urologia. Area de Medicina Sexual.Hospital Universitario Puerta de Hierro-Majadahonda. Madrid.Spain Division of Urology. Beth Israel Deaconess Medical Center. Harvard Medical School.Boston Massachusetts.USA.Servicio de Urologia. Clinica La Zarzuela.Madrid.Spain.
Abstract:
Testosterone Deficiency Syndrome is associated with age. Recent studies advocate for the safety of hormonal treatment with testosterone in patients with history of Prostate Cancer (PC) ,once disease-free survival is confirmed. A total of five publications describe 110 patients treated with testosterone replacement therapy, having a history of PC, who had undergone radical prostatectomy (RP). Only one patient had biochemical recurrence during replacement therapy. Testosterone replacement therapy must be indicated in selected patients with history of low risk localized prostate cancer treated satisfactorily who are symptomatic and have good oncological control. The testosterone levels to achieve should be the minimum effective to obtain a symptomatic response. Adequate information on the benefits and potential risks must be understood and accepted by the patient.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Menopause
Urinary Tract Calculi VI: Surgical Management

